Atea Pharmaceuticals’ benifobuvir sulfate for hepatitis C treatment: Likelihood of approval

In addition to indication benchmarks based on 18 years of historical drug development data, GlobalData also tracks the likelihood of phase change and approval scores for specific drugs. The attributes of the drug, the company, and its clinical trials play an important role in drug-specific PTSR and likelihood of approval.

Benifobuvir sulfate overview

AT-527 is being developed for the treatment of chronic hepatitis C virus infection and coronavirus COVID-19 disease. The drug candidate is a pan-genotypic purine nucleotide prodrug NS5B polymerase inhibitor. It is administered by the oral route in tablet form. The drug candidate is developed based on a purine nucleotide prodrug platform.

It is also being developed to treat the coronavirus COVID-19 disease.

Atea Pharmaceuticals Overview

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company. It develops, discovers and commercializes therapies to treat life-threatening viral infections. The company’s product pipeline includes bemnifosbuvir (AT-527) for the treatment of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and bemnifosbuvir with ruzasvir for the treatment of hepatitis C combination virus (HCV). Atea Pharmaceuticals launches purine nucleotide prodrug platform to transform treatment of severe viral diseases. It also includes the development of oral antiviral drugs for severe viral infections. Atea Pharmaceuticals is headquartered in Boston, Massachusetts, USA.

For complete information on drug-specific PTSR and LoA scores for benifobuvir sulfate, purchase the report here.

Desde

The gold standard in business intelligence.

GlobalData’s unparalleled proprietary data combines expertise with cutting-edge technology, allowing you to decipher what’s happening in the market. You can make smarter decisions and gain a future-proof advantage over your competitors.

better understand the situation